Imnovid 4 mg Capsule

Description

Imnovid, when used alongside bortezomib and dexamethasone, is approved for treating adults with multiple myeloma who have undergone at least one prior treatment with lenalidomide. In cases of relapsed and refractory multiple myeloma, Imnovid combined with dexamethasone is recommended for adults who have received at least two previous treatment regimens involving lenalidomide and bortezomib, and have shown disease progression after their most recent therapy. Pomalidomide, in conjunction with bortezomib and dexamethasone, should be initiated at a 4 mg oral daily dose on Days 1 to 14 of 21-day cycles—the dosages of bortezomib and dexamethasone in combination with pomalidomide. For bortezomib, the recommended starting dose is 1.3 mg/m² administered intravenously or subcutaneously once daily. Dexamethasone should be taken orally at a 20 mg daily dose as prescribed.